The Universal Selection Source:
Adhesives Ingredients
Industry News

UPM Raflatac at CPhl 2017: to Unveil Labeling Solutions for Medical Device & Healthcare Applications

Published on 2017-10-23. Author : SpecialChem

UPM Raflatac will be present at the CPhl Innopack exhibition on 24–26 October 2017 in Frankfurt, Germany. Visitors will have the opportunity to discuss market developments and the latest solutions with UPM Raflatac’s pharmaceutical labeling experts in Hall 4.2, Stand 42J50.

Labels for cold and cryogenic use
Labels for Cold and Cryogenic Use

Multi-faceted Adhesive

  • UPM Raflatac will launch a brand new product range for medical device and healthcare industry.
  • New RPMD is a multi-faceted adhesive that is ideal for labeling medical devices. 
  • Selection of different face materials with new RPMD adhesive are specially designed for different medical device sub-segments such as sterilization wraps and bags, infusion bags and bottles, drug-device combinations like pens, auto-injectors and inhalers and blood donation labeling. 
  • RPMD adhesive combines excellent adhesion with a tight mandrel hold on glass and plastic and is sterilization resistant and migration safe.

Markku Pietarinen, Manager, Business Segments & Pharma, Specials EMEIA, says:

“In April 2017 the EU Commission formally adopted two new regulations on medical devices and in vitro diagnostic medical devices. One of the main regulatory updates is the implementation of a Unique Device Identification system (UDI) that provides a globally harmonized and consistent approach for the marking and identification of medical devices.”

Blood bag and IV solutions
Blood bag and IV Solutions
“A UDI is a code printed on a label affixed to a device or its packaging, or even directly on the device itself, in both plain text and machine-readable format. All medical devices available in the EU must comply with the new regulations by April 2020, with the deadline for in vitro diagnostic devices falling two years later, in 2022.”

Compliant with Falsified Medicines Directive

Among UPM Raflatac’s most recent innovations is also a range of pharmaceutical labeling materials which support compliance with the Falsified Medicines Directive (2011/62/EU) regarding packaging for prescription drugs and high-risk, over-the-counter medicines. An estimated 30 billion such packs issued annually are affected in the EU. The deadline for compliance is February 2019 in the majority of EU member states.

The RP62 EU adhesive supplied with these tamper-verification products creates cardboard tear on typically used cardboard cartons carrying a water-based varnish. Its paper-based and filmic label faces all pair with RP62 EU adhesive are supporting legislative requirements for individually authenticated, tamper-evident packs, protecting the supply chain from counterfeits.

PS: If you liked this News, you might enjoy our Adhesives Industry Newsletter. All the Industry News delivered once a week right to your inbox. Sign up here!

Source: UPM Raflatac
Improve your performance with water soluble epoxy compounds
Process oils for non-woven adhesives
Channel Alerts

Receive weekly digests on hot topics

Back to Top